Evidence map›Paper›PMID 34981503›Full record

ReviewAdvances in experimental medicine and biology2021

Naturally Occurring SGLT2 Inhibitors: A Review.

Habib Yaribeygi, Milad Ashrafizadeh, Thozhukat Sathyapalan, Tannaz Jamialahmadi, Amirhossein Sahebkar

Abstract readReview
PubMed Publisher
In one paragraph

Review in Advances in experimental medicine and biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.2field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 4 countries.

Habib YaribeygiResearch Center of Physiology, Semnan University of Medical Sciences, Semnan, Iran. habib.yari@yahoo.com.
Milad AshrafizadehFaculty of Engineering and Natural Sciences, Sabanci University, Istanbul, Turkey.
Thozhukat SathyapalanAcademic Diabetes, Endocrinology and Metabolism, Hull York Medical School, University of Hull, Hull, UK.
Tannaz JamialahmadiDepartment of Food Science and Technology, Quchan Branch, Islamic Azad University, Quchan, Iran.
Amirhossein SahebkarBiotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran. sahebkara@mums.ac.ir.
Islamic Azad University Quchan · IRMashhad University of Medical Sciences · IRSabancı Üniversitesi · TRSemnan University of Medical Sciences · IRUniversity of Hull · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With an increasing incidence of diabetes mellitus globally due to various factors, including unhealthy lifestyle, there is a need for developing novel drugs for the management of diabetes. This chronic metabolic disorder results in high blood glucose levels due to the body's inability to reduce the concentration of glucose. The decreased secretion of insulin and increased resistance to insulin action contribute to the development of diabetes mellitus. There have been efforts to target pathways involved in the metabolism of blood glucose. It seems that most of the currently applied antidiabetic medications are associated with unwanted side effects. Hence, it appears that plant-derived chemicals can be considered as potential candidates in the management of diabetes. Sodium-glucose cotransporter inhibitors (SGLT2i) are synthetic hypoglycemic medications approved for managing patients with diabetes in lowering blood glucose. SGLT2i reduces blood glucose concentration by enhancing its urinary excretion and inhibition of its absorption through the kidney. It has been demonstrated that some of the naturally occurring nutraceutical agents can imitate the action of SGLT2i and, consequently, diminish the level of blood glucose. At the present review, we have discussed the phytochemicals that act like SGLT2i to decrease blood glucose level.

Indexed as

Diabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsBlood GlucoseHumansHypoglycemic AgentsInsulinBlood GlucoseHypoglycemic AgentsInsulinSodium-Glucose Transporter 2 InhibitorsAntidiabetic medicationsDiabetesGlucoseHerbal medicineSGLT2i

Identifiers

PMID34981503
OpenAlexW4206478008

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.